AC007461.1 | Uncharacterized protein | | | | | | Tissue enhanced |
AC020907.1 | Uncharacterized protein | | | | | | Tissue enhanced |
AC120194.1 | | Predicted membrane proteins
| | | | | Tissue enhanced |
ANO1 | Anoctamin 1, calcium activated chloride channel | FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
AQP5 | Aquaporin 5 | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
ATP13A5 | ATPase type 13A5 | Predicted membrane proteins
| | | | | Tissue enhanced |
ATP2B2 | ATPase, Ca++ transporting, plasma membrane 2 | Enzymes Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
ATP6V1B1 | ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B1 | Disease related genes
| | | | | Tissue enhanced |
AZGP1 | Alpha-2-glycoprotein 1, zinc-binding | Cancer-related genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
BARX2 | BARX homeobox 2 | Transcription factors
| | | | | Tissue enhanced |
BPIFB1 | BPI fold containing family B, member 1 | Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
BPIFB4 | BPI fold containing family B, member 4 | Predicted secreted proteins
| | | | | Tissue enhanced |
BSPRY | B-box and SPRY domain containing | | | | | | Tissue enhanced |
C17orf107 | Chromosome 17 open reading frame 107 | | | | | | Tissue enhanced |
C17orf77 | Chromosome 17 open reading frame 77 | | | | | | Tissue enhanced |
C1orf64 | Chromosome 1 open reading frame 64 | | | | | | Tissue enhanced |
C21orf37 | Chromosome 21 open reading frame 37 | | | | | | Tissue enhanced |
C5orf38 | Chromosome 5 open reading frame 38 | | | | | | Tissue enhanced |
CCDC129 | Coiled-coil domain containing 129 | Predicted secreted proteins
| | | | | Tissue enhanced |
CCDC160 | Coiled-coil domain containing 160 | | | | | | Tissue enhanced |
CHRM3 | Cholinergic receptor, muscarinic 3 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
CLDN10 | Claudin 10 | Predicted membrane proteins
| | | | | Tissue enhanced |
CNTN5 | Contactin 5 | Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
COL28A1 | Collagen, type XXVIII, alpha 1 | Predicted secreted proteins
| | | | | Tissue enhanced |
COL9A3 | Collagen, type IX, alpha 3 | Disease related genes Predicted secreted proteins
| | | | | Tissue enhanced |
CRISP3 | Cysteine-rich secretory protein 3 | Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CTB-102L5.4 | | | | | | | Tissue enhanced |
CTB-50L17.14 | Uncharacterized protein | | | | | | Tissue enhanced |
CTC-236F12.4 | Uncharacterized protein | | | | | | Tissue enhanced |
DEFB1 | Defensin, beta 1 | Predicted secreted proteins Transporters
| | | | | Tissue enhanced |
EDN3 | Endothelin 3 | Disease related genes Predicted secreted proteins
| | | | | Tissue enhanced |
EFCAB4A | EF-hand calcium binding domain 4A | | | | | | Tissue enhanced |
EFCAB4B | EF-hand calcium binding domain 4B | | | | | | Tissue enhanced |
ETV1 | Ets variant 1 | Cancer-related genes Disease related genes Transcription factors
| | | | | Tissue enhanced |
FAM196B | Family with sequence similarity 196, member B | | | | | | Tissue enhanced |
FAM20A | Family with sequence similarity 20, member A | Disease related genes Predicted secreted proteins
| | | | | Tissue enhanced |
FAM3D | Family with sequence similarity 3, member D | Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
FDCSP | Follicular dendritic cell secreted protein | Predicted secreted proteins
| | | | | Tissue enhanced |
FOLR1 | Folate receptor 1 (adult) | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
FOXI1 | Forkhead box I1 | Plasma proteins Transcription factors
| | | | | Tissue enhanced |
FXYD6-FXYD2 | FXYD6-FXYD2 readthrough | Predicted membrane proteins
| | | | | Tissue enhanced |
GPR12 | G protein-coupled receptor 12 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
GRIN2C | Glutamate receptor, ionotropic, N-methyl D-aspartate 2C | FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
HCAR1 | Hydroxycarboxylic acid receptor 1 | G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
HSD11B2 | Hydroxysteroid (11-beta) dehydrogenase 2 | Disease related genes Predicted membrane proteins
| | | | | Tissue enhanced |
IRX1 | Iroquois homeobox 1 | Plasma proteins Transcription factors
| | | | | Tissue enhanced |
IRX2 | Iroquois homeobox 2 | Transcription factors
| | | | | Tissue enhanced |
IRX5 | Iroquois homeobox 5 | Disease related genes Transcription factors
| | | | | Tissue enhanced |
ISL2 | ISL LIM homeobox 2 | Transcription factors
| | | | | Tissue enhanced |
KCNN4 | Potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 | FDA approved drug targets Predicted membrane proteins Predicted secreted proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |